阿托伐他汀等药物对高脂血症大鼠血小板功能的影响  

The intervention effect of atorvastatin,losartan,compound Danshen dripping pills and prostaglandin E_1 on the platelet function of hyperlipemia rats

作　　者：王志军[1] 柯元南[2] 程文立[2] 于长安[2] 温见艳[2] 杨鹏[2] 陈旺[3] 

机构地区：[1]华北煤炭医学院附属医院心内科,河北唐山063000 [2]卫生部中日友好医院心内科,北京100029 [3]卫生部中日友好医院临研所试验动物中心,北京100029

出　　处：《中国医院药学杂志》2008年第8期611-615,共5页Chinese Journal of Hospital Pharmacy

摘　　要：目的:分析高脂血症大鼠血小板功能的变化,探讨阿托伐他汀、氯沙坦、复方丹参滴丸、前列腺素E1对高脂血症大鼠血小板功能的影响。方法:64只Wistar大鼠随机分为正常对照组、高脂血症模型组、阿托伐他汀组(阿乐,10mg.kg-1.d-1)、氯沙坦组(科素亚,20mg.kg-1.d-1)、复方丹参滴丸组(160mg.kg-1.d-1)、前列腺素E1(凯时,4μg.kg-1.d-1)注射液组干预组。分组进行干预后检测6组大鼠的血脂:总胆固醇(CHO)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)的水平。应用酶联免疫法测定血浆中GMP140浓度、流式细胞术检测血小板表面CD62P的表达。结果:正常对照组与高脂血症组CHO、LDL-C、HDL-C/CHO分别是1.846vs13.779mmol.L-1、0.164vs10.680mmol.L-1、0.583vs0.195。GMP140、CD62P水平分别为10.655vs27.045μg.L-1、10.089%vs25.169%,差别显著。阿托伐他汀组CHO、LDL-C、HDL-C/CHO、GMP140、CD62P为7.053mmol.L-1、4.659mmol.L-1、0.31、13.371μg.L-1和9.983%。氯沙坦组上述指标是14.570mmol.L-1、11.393mmol.L-1、0.216、20.665μg.L-1和20.144%。复方丹参滴丸及前列腺E1组上述指标分别为10.927mmol.L-1、8.081mmol.L-1、0.239,13.999μg.L-1、10.476%和14.962monol.L-1,11.074mmol.L-1、0.255、21.040μg.L-1和17.089%。结论:高脂血症能够促使血小板活化,阿托伐他汀在调脂治疗的同时,能够改善血小板的功能、抑制了血小板的活化。科素亚、复方丹参滴丸、前列腺素E1均具有抑制血小板活化的作用。阿托伐他汀和复方丹参滴丸抑制血小板活化的作用强于氯沙坦和前列腺素E1。阿托伐他汀及复方丹参滴丸效果相似,氯沙坦与前列腺素E1组效果相似。OBJECTIVE To analyze the platelet function change of hyperlipemia rats and evaluate the intervention effect of atorvastatin, losartan, compound Danshen dripping pills and prostaglandin E1 on the platelet function of them. METHODS Sixty-four Wistar rats were randomLy divided into six groups： control group, hyperlipidemic group, atorvastatin treated group （Ale, 10 mg·kg^-1·d^-1）, losartan treated group （Kesuya, 20 mg·kg^-1·d^-1）, compound Danshen dripping pills treated group （ 160 mg·kg^-1·d^-1 ） and prostaglandin E1 treated group （Kaishi, 4 μg·kg^-1·d^-1）. After four weeks of intervention, the serum levels of lipid （include CHO, TG, LDL-C and HDL-C） were measured. Euzymelinked immunosorbent assay was used to detect the serum levels of GMP140. Flow cytometric analysis was applied to detect the expression of CD62 on the surface of platelet. RESULTS The serum level of CHO, LDL-C, HDL-C/CHO, GMP140 and CD62P of control rats compared with those of hyperlipidemic subjects were 1. 846 vs 13. 779 mmol·L^-1 ,0. 164 vs 10.680 mmol·L^-1 ,0. 583 vs 0. 195,10. 665 vs 27. 045 μg·L^-1 and 10. 089% vs 25. 169%. The level of above-mentioned indicos of atorvastatin treated group were 7. 053 mmol·L^-1,4. 659 mmol·L^-1 ,0. 312, 13. 371 μg·L^-1 and 9. 983%. Those of losartan treated group were 14.570 mmol·L^-1 , 11. 393 mmol·L^-1 ,0. 216,20. 665 μg·L^-1 and 20. 144%. Indices of compound Danshen dripping pills treated and prostaglandin E1 treated group were 10. 927 mmol·L^-1,8. 081 mmol·L^-1,0. 239,13. 999 μg·L^-1 ,10. 476% and 14. 962 mmol·L^-1 ,11. 074 mmol·L^-1 ,0. 255,21. 040 μg·L^-1 , 17. 089% respectively. CONCLUSION Hyperlipidemic can enhance platelet activation. Atorvastatin can not only regulate dyslipidemia but also improve platelet function and refrain the activation of platelet. Losartan can refrain platelet activation too, So do compound Danshen dripping pills and prostaglandin E1. The improving platelet function effect of atorvastatin and compound Danshen dripping pills i

关 键 词：阿托伐他汀 科素亚 复方丹参滴丸 前列腺E1 高脂血症大鼠 血小板功能 

分 类 号：R963[医药卫生—微生物与生化药学]